A primer on how Profit Catalyst Alert works options into the mix of trade suggestions. Also, in defense of Steelcase, which got whacked unfairly, and why I like Chemours so much. Read More
Linda McDonough is a veteran hedge fund analyst who loves to break down company financial statements and identify market inefficiencies to uncover big opportunities. She believes in a boots-on-the-ground approach that includes surveying customers, interviewing company executives, or doing whatever it takes to see what others don't.
She's now brought her experience as a hedge fund analyst to subscribers of her Profit Catalyst Alert service. Her system identifies small- and mid-cap stocks that are about to move due to catalytic events that few others can identify...until it's too late. These events often times result in massive gains for her followers.
Farmers are getting squeezed once again. 2018 is shaping up to be another year of pain for farmers, who will continue to postpone purchases of agriculture equipment. Buy put options on these farm equipment manufacturers. Read More
I suggest selling the July Chemours call options (recommended in March) as the expiration is looming and the stock showing little chance of closing well above the $50 strike price. I still like the prospects of Chemours and believe the October call options should give enough time for the bull story to play out. Read More
Tariff fears have dragged down the Chemours (NYSE: CC) enough that the July $50 calls are not likely to recoup much of their losses before the expiration date. I suggest selling these for a small portion of our purchase price and using those proceeds to buy the October series. See my buy alert for the October $49 calls under a separate alert. Read More
I am keeping Tapestry (NYSE: TPR) in the portfolio as a long but suggest selling these call options which have doubled in two weeks time. Read More
Rising estimates support the increased price targets on Systemax and Carbonite but PRA Health must be sold on valuation. I'll be watching this quality player in the healthcare space for a better entry point in the future. Also, Ichor continues to droop- what will send the shares higher? Read More
PRA Health has had a terrific run in the past month without a coincident increase in estimates. The stock hit my target and I cannot justify a higher one. The fundamentals are sound on the stock, this is a pure valuation call. Read More